Bial investing EUR 110m in expansion in the US, including biotechnology center focused on Parkinson's disease
|
01 OCT 2020
|
Intel ID : 302348
|
||||
| Intel ID | 302348 | |
| Value | EUR 110,00m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Bial
(31 Dec 2023) |
Revenue: EUR 293,08m EBITDA: EUR 67,43m Net Debt: EUR 123,36m People: 388 |
|
| Date |
 |
|
| Country | |
|
| Geography |  |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Mergers & Acquisitions
| Date | Target | Country | Buyer | Seller | VALUE (EURm) | Subsector | |||
|
|
|
|
|
|
|
|
 |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.